Class III lanthipeptides are an emerging subclass of
lanthipeptides,
representing an underexplored trove of new natural products with potentially
broad chemical diversity and important biological activity. Bioinformatic
analysis of class III lanthipeptide biosynthetic gene cluster (BGC)
distribution has revealed their high abundance in the phylum Firmicutes.
Many of these clusters also feature methyltransferase (MT) genes,
which likely encode uncommon class III lanthipeptides. However, two
hurdles, silent BGCs and low-yielding pathways, have hindered the
discovery of class III lanthipeptides from Firmicutes. Here, we report
the design and construction of a biosynthetic pathway refactoring
and heterologous overexpression strategy which seeks to overcome these
hurdles, simultaneously activating and increasing the production of
these Firmicutes class III lanthipeptides. Applying our strategy to
MT-containing BGCs, we report the discovery of new class III lanthipeptides
from Firmicutes bearing rare N,N-dimethylations. We reveal the importance of the first two amino
acids in the N-terminus of the core peptide in controlling the MT
dimethylation activity. Leveraging this feature, we engineer class
III lanthipeptides to enable N,N-dimethylation, resulting in significantly increased antibacterial
activity. Furthermore, the refactoring and heterologous overexpression
strategy showcased in this study is potentially applicable to other
ribosomally synthesized and post-translationally modified peptide
BGCs from Firmicutes, unlocking the genetic potential of Firmicutes
for producing peptide natural products.